103 related articles for article (PubMed ID: 23362288)
41. Telemedicine in corrections.
Hammack GG
Curr Probl Dermatol; 2003; 32():148-52. PubMed ID: 12472004
[No Abstract] [Full Text] [Related]
42. Nurse-led model boosts uptake of type 2 diabetes treatment.
Nurs Stand; 2017 Mar; 31(31):16. PubMed ID: 28351262
[TBL] [Abstract][Full Text] [Related]
43. Enhancing assessment and treatment of hepatitis C in the custodial setting.
Post JJ; Arain A; Lloyd AR
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S70-4. PubMed ID: 23884069
[TBL] [Abstract][Full Text] [Related]
44. Adherence and sustained virologic response among vulnerable people initiating an hepatitis C treatment at a nurse-led clinic: A non-experimental prospective cohort study based on clinical records.
Gagné M; Têtu I; Grégoire JP; Moisan J
Int J Nurs Stud Adv; 2021 Nov; 3():100029. PubMed ID: 38746734
[TBL] [Abstract][Full Text] [Related]
45. Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit.
Walker SJ; Shrestha LB; Lloyd AR; Dawson O; Sheehan Y; Sheehan J; Maduka NBC; Cabezas J; Akiyama MJ; Kronfli N;
Int J Drug Policy; 2024 Apr; 126():104386. PubMed ID: 38492433
[TBL] [Abstract][Full Text] [Related]
46. Implementing interprofessional video consultations with general practitioners and psychiatrists in correctional facilities in Germany: results from a mixed-methods study.
Colombo MG; Joos S; Koch R
BMC Health Serv Res; 2023 Jun; 23(1):578. PubMed ID: 37277811
[TBL] [Abstract][Full Text] [Related]
47. Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be?
Kronfli N; Buxton JA; Jennings L; Kouyoumdjian F; Wong A
Can Liver J; 2019; 2(4):171-183. PubMed ID: 35992759
[TBL] [Abstract][Full Text] [Related]
48. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience.
Winter RJ; Holmes JA; Papaluca TJ; Thompson AJ
Viruses; 2022 Feb; 14(3):. PubMed ID: 35336905
[TBL] [Abstract][Full Text] [Related]
49. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
50. Regional progress towards hepatitis C elimination in the Western Pacific Region, 2015-2020.
Chan PL; Le LV; Ishikawa N; Easterbrook P
Glob Health Med; 2021 Oct; 3(5):253-261. PubMed ID: 34782866
[TBL] [Abstract][Full Text] [Related]
51. A nurse practitioner model of care in the era of direct acting antiviral therapy for hepatitis C virus infection.
Nario S; Reynauld B; Blacklaws H; Boden S; Sud R; Hawken G; Singh S; Herba K; Panetta J; Pang J
JGH Open; 2021 Jun; 5(6):669-672. PubMed ID: 34124384
[TBL] [Abstract][Full Text] [Related]
52. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
[TBL] [Abstract][Full Text] [Related]
53. Innovations in Hepatitis C Screening and Treatment.
Patel AA; Bui A; Prohl E; Bhattacharya D; Wang S; Branch AD; Perumalswami PV
Hepatol Commun; 2021 Mar; 5(3):371-386. PubMed ID: 33681673
[TBL] [Abstract][Full Text] [Related]
54. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.
Wong YJ; Thurairajah PH; Kumar R; Fock KM; Law NM; Chong SY; Manejero FG; Ang TL; Teo EK; Tan J
Clin Mol Hepatol; 2021 Jul; 27(3):474-485. PubMed ID: 33601868
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
Kwon JA; Chambers GM; Luciani F; Zhang L; Kinathil S; Kim D; Thein HH; Botha W; Thompson S; Lloyd A; Yap L; Gray RT; Butler T
PLoS One; 2021; 16(2):e0245896. PubMed ID: 33571196
[TBL] [Abstract][Full Text] [Related]
56. Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan.
Yang TH; Fang YJ; Hsu SJ; Lee JY; Chiu MC; Yu JJ; Kuo CC; Chen CH
Open Forum Infect Dis; 2020 Aug; 7(8):ofaa301. PubMed ID: 32818142
[TBL] [Abstract][Full Text] [Related]
57. Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.
Ocal S; Muir AJ
Curr HIV/AIDS Rep; 2020 Feb; 17(1):18-25. PubMed ID: 31933274
[TBL] [Abstract][Full Text] [Related]
58. Integrating primary and secondary care to optimize hepatitis C treatment: development and evaluation of a multidisciplinary educational Masterclass series.
McCombe G; Almaazmi B; Cullen W; Lambert JS; Avramovic G; Murphy C; O'Connor M; Perry N; Ianache I; Lazar S; McHugh T; Surey J; Macías J; Vickerman P; Oprea C
J Antimicrob Chemother; 2019 Nov; 74(Suppl 5):v24-v30. PubMed ID: 31782501
[TBL] [Abstract][Full Text] [Related]
59. The Current and Future Use of Telemedicine in Infectious Diseases Practice.
Coombes CE; Gregory ME
Curr Infect Dis Rep; 2019 Oct; 21(11):41. PubMed ID: 31630276
[TBL] [Abstract][Full Text] [Related]
60. Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.
Crowley D; Cullen W; Lambert JS; Van Hout MC
PLoS One; 2019; 14(9):e0222186. PubMed ID: 31509571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
